Karyopharm Therapeutics Inc. (KPTI) vs NanoViricides, Inc. (NNVC)

Karyopharm Therapeutics Inc. and NanoViricides, Inc. are both Biotechnology companies. Karyopharm Therapeutics Inc. and NanoViricides, Inc. are of similar size ($39.2M and $38.0M). NanoViricides, Inc. has the higher net margin (0.00% vs −153.3%) and the lower return on invested capital (−86.0% vs 0.00%). Across the 13 metrics below, NanoViricides, Inc. leads on 8 and Karyopharm Therapeutics Inc. on 5.

Valuation

Metric KPTI NNVC Biotechnology median
P/E n/m n/m 7.88
P/S 0.32 n/m 11.47
P/B n/m 3.40 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.58 n/m 10.73
Earnings yield (874.99%) (29.86%) (28.84%)
Free cash flow yield (139.70%) (23.69%) (23.03%)

Profitability

Metric KPTI NNVC Biotechnology median
Gross margin 95.89% 0.00% 65.16%
Operating margin (56.17%) 0.00% 0.00%
Net margin (153.28%) 0.00% 0.00%
Free cash flow margin (44.57%) 0.00% 0.00%
Return on equity 78.98% (89.97%) (57.72%)
Return on assets (207.90%) (79.91%) (49.22%)
Return on invested capital 0.00% (86.02%) 0.00%

Growth

Metric KPTI NNVC Biotechnology median
Revenue growth (TTM) 6.81% — 5.64%
EPS growth (last fiscal year) (98.37%) 10.00% —
Revenue growth, 5-year CAGR 6.21% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KPTI NNVC Biotechnology median
Debt to equity (0.76) 0.00 0.00
Current ratio 0.79 3.17 4.73
Net debt to EBITDA (2.03) 0.18 0.96

Dividend

Metric KPTI NNVC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric KPTI NNVC Biotechnology median
Market cap 39.24m 38.04m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack